Publication:
Mesoporous Silica Nanoparticles for Co-Delivery of Drugs and Nucleic Acids in Oncology: A Review

dc.contributor.authorParis, Juan L.
dc.contributor.authorVallet-Regí, María
dc.contributor.authoraffiliation[Paris,JL] Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Civil, Málaga, Spain. [Paris,JL] Nanostructures for Diagnosing and Treatment of Allergic Diseases Laboratory, Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Málaga, Spain. [Vallet-Regí,M] Departamento de Química en Ciencias Farmacéuticas (Unidad Docente de Química Inorgánica y Bioinorgánica), Facultad de Farmacia, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain. [Vallet-Regí,M] Centro de Investigación Biomédicaen Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Spain.
dc.date.accessioned2024-02-12T19:46:27Z
dc.date.available2024-02-12T19:46:27Z
dc.date.issued2020-06-08
dc.description.abstractMesoporous silica nanoparticles have attracted much attention in recent years as drug and gene delivery systems for biomedical applications. Among their most beneficial features for biomedicine, we can highlight their biocompatibility and their outstanding textural properties, which provide a great loading capacity for many types of cargos. In the context of cancer nanomedicine, combination therapy and gene transfection/silencing have recently been highlighted as two of its most promising fields. In this review, we aim to provide an overview of the different small molecule drug-nucleic acid co-delivery combinations that have been developed using mesoporous silica nanoparticles as carriers. By carefully selecting the chemotherapeutic drug and nucleic acid cargos to be co-delivered by mesoporous silica nanoparticles, different therapeutic goals can be achieved by overcoming resistance mechanisms, combining different cytotoxic mechanisms, or providing an additional antiangiogenic effect. The examples here presented highlight the great promise of this type of strategies for the development of future therapeutics.
dc.description.sponsorshipThis paper was funded by the European Research Council (Grant VERDI; ERC-2015 AdG no. 694160). J.L.P. was supported by a Sara Borrell research contract from the Institute of Health ‘Carlos III’ of the Ministry of Science and Innovation (grant cofounded by European Social Fund (ESF), reference CD19/00250CP15/00103).
dc.identifier.doi10.3390/pharmaceutics12060526
dc.identifier.e-issn1999-4923es_ES
dc.identifier.journalPharmaceuticses_ES
dc.identifier.otherhttp://hdl.handle.net/10668/3585
dc.identifier.pubmedID32521800es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18061
dc.language.isoeng
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/12/6/526/htmes
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectMesoporous silica nanoparticles
dc.subjectCo-delivery
dc.subjectDrug delivery
dc.subjectNucleic acids
dc.subjectGene transfection
dc.subjectNanomedicine
dc.subjectDióxido de silicio
dc.subjectNanopartículas
dc.subjectSistemas de liberación de medicamentos
dc.subjectÁcidos nucleicos
dc.subjectTransfección
dc.subjectNanomedicina
dc.subject.meshSilicon Dioxide
dc.subject.meshNucleic Acids
dc.subject.meshNanoparticles
dc.subject.meshDrug Delivery Systems
dc.subject.meshTransfection
dc.subject.meshNanomedicine
dc.subject.meshGene Transfer Techniques
dc.titleMesoporous Silica Nanoparticles for Co-Delivery of Drugs and Nucleic Acids in Oncology: A Review
dc.typereview article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isPublisherOfPublication30293a55-0e53-431f-ae8c-14ab01127be9
relation.isPublisherOfPublication.latestForDiscovery30293a55-0e53-431f-ae8c-14ab01127be9

Files